nodes	percent_of_prediction	percent_of_DWPC	metapath
Dapagliflozin—CYP2A6—Prednisolone—ankylosing spondylitis	0.16	0.179	CbGbCtD
Dapagliflozin—CYP2A6—Dexamethasone—ankylosing spondylitis	0.0941	0.105	CbGbCtD
Dapagliflozin—ABCB1—Methylprednisolone—ankylosing spondylitis	0.0831	0.0929	CbGbCtD
Dapagliflozin—CYP1A1—Dexamethasone—ankylosing spondylitis	0.0804	0.0899	CbGbCtD
Dapagliflozin—ABCB1—Betamethasone—ankylosing spondylitis	0.054	0.0604	CbGbCtD
Dapagliflozin—ABCB1—Prednisolone—ankylosing spondylitis	0.0533	0.0596	CbGbCtD
Dapagliflozin—ABCB1—Prednisone—ankylosing spondylitis	0.0503	0.0563	CbGbCtD
Dapagliflozin—CYP3A4—Methylprednisolone—ankylosing spondylitis	0.0498	0.0557	CbGbCtD
Dapagliflozin—CYP3A4—Triamcinolone—ankylosing spondylitis	0.0377	0.0422	CbGbCtD
Dapagliflozin—CYP2C9—Dexamethasone—ankylosing spondylitis	0.0324	0.0362	CbGbCtD
Dapagliflozin—CYP3A4—Betamethasone—ankylosing spondylitis	0.0324	0.0362	CbGbCtD
Dapagliflozin—CYP3A4—Prednisolone—ankylosing spondylitis	0.0319	0.0357	CbGbCtD
Dapagliflozin—ABCB1—Dexamethasone—ankylosing spondylitis	0.0314	0.0351	CbGbCtD
Dapagliflozin—CYP3A4—Prednisone—ankylosing spondylitis	0.0302	0.0337	CbGbCtD
Dapagliflozin—CYP2D6—Dexamethasone—ankylosing spondylitis	0.0296	0.0331	CbGbCtD
Dapagliflozin—ABCB1—Methotrexate—ankylosing spondylitis	0.0252	0.0282	CbGbCtD
Dapagliflozin—CYP3A4—Dexamethasone—ankylosing spondylitis	0.0188	0.021	CbGbCtD
Dapagliflozin—Carcinogenicity—Methotrexate—ankylosing spondylitis	0.0123	0.128	CcSEcCtD
Dapagliflozin—Multiple fractures—Methylprednisolone—ankylosing spondylitis	0.00193	0.02	CcSEcCtD
Dapagliflozin—Fracture—Methylprednisolone—ankylosing spondylitis	0.00193	0.02	CcSEcCtD
Dapagliflozin—Fracture—Betamethasone—ankylosing spondylitis	0.00176	0.0182	CcSEcCtD
Dapagliflozin—Fracture—Dexamethasone—ankylosing spondylitis	0.00176	0.0182	CcSEcCtD
Dapagliflozin—Multiple fractures—Dexamethasone—ankylosing spondylitis	0.00176	0.0182	CcSEcCtD
Dapagliflozin—Multiple fractures—Betamethasone—ankylosing spondylitis	0.00176	0.0182	CcSEcCtD
Dapagliflozin—SLC5A4—Orphan transporters—ANO6—ankylosing spondylitis	0.00173	0.189	CbGpPWpGaD
Dapagliflozin—Multiple fractures—Prednisone—ankylosing spondylitis	0.00153	0.0158	CcSEcCtD
Dapagliflozin—Fracture—Prednisone—ankylosing spondylitis	0.00153	0.0158	CcSEcCtD
Dapagliflozin—Fungal infection—Methylprednisolone—ankylosing spondylitis	0.00145	0.0151	CcSEcCtD
Dapagliflozin—Fungal infection—Betamethasone—ankylosing spondylitis	0.00132	0.0137	CcSEcCtD
Dapagliflozin—Fungal infection—Dexamethasone—ankylosing spondylitis	0.00132	0.0137	CcSEcCtD
Dapagliflozin—SLC5A2—Orphan transporters—ANO6—ankylosing spondylitis	0.00131	0.143	CbGpPWpGaD
Dapagliflozin—SLC5A1—Orphan transporters—ANO6—ankylosing spondylitis	0.00131	0.143	CbGpPWpGaD
Dapagliflozin—Fracture—Methotrexate—ankylosing spondylitis	0.00128	0.0132	CcSEcCtD
Dapagliflozin—Multiple fractures—Methotrexate—ankylosing spondylitis	0.00128	0.0132	CcSEcCtD
Dapagliflozin—Extravasation—Dexamethasone—ankylosing spondylitis	0.00117	0.0121	CcSEcCtD
Dapagliflozin—Extravasation—Betamethasone—ankylosing spondylitis	0.00117	0.0121	CcSEcCtD
Dapagliflozin—Fungal infection—Prednisone—ankylosing spondylitis	0.00115	0.0119	CcSEcCtD
Dapagliflozin—Lung disorder—Methotrexate—ankylosing spondylitis	0.00105	0.0109	CcSEcCtD
Dapagliflozin—Diabetes mellitus—Prednisolone—ankylosing spondylitis	0.00102	0.0106	CcSEcCtD
Dapagliflozin—Fungal infection—Methotrexate—ankylosing spondylitis	0.000963	0.00996	CcSEcCtD
Dapagliflozin—Diabetes mellitus—Triamcinolone—ankylosing spondylitis	0.00094	0.00972	CcSEcCtD
Dapagliflozin—Diabetes mellitus—Methylprednisolone—ankylosing spondylitis	0.000937	0.0097	CcSEcCtD
Dapagliflozin—Diabetes mellitus—Betamethasone—ankylosing spondylitis	0.000852	0.00882	CcSEcCtD
Dapagliflozin—Diabetes mellitus—Dexamethasone—ankylosing spondylitis	0.000852	0.00882	CcSEcCtD
Dapagliflozin—Extravasation—Methotrexate—ankylosing spondylitis	0.000852	0.00882	CcSEcCtD
Dapagliflozin—Diabetes mellitus—Prednisone—ankylosing spondylitis	0.000742	0.00768	CcSEcCtD
Dapagliflozin—Influenza—Triamcinolone—ankylosing spondylitis	0.000706	0.00731	CcSEcCtD
Dapagliflozin—Vaginal infection—Methotrexate—ankylosing spondylitis	0.000702	0.00726	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Prednisolone—ankylosing spondylitis	0.000675	0.00698	CcSEcCtD
Dapagliflozin—Urine output increased—Methotrexate—ankylosing spondylitis	0.000672	0.00695	CcSEcCtD
Dapagliflozin—Neoplasm—Methotrexate—ankylosing spondylitis	0.000672	0.00695	CcSEcCtD
Dapagliflozin—Myocardial infarction—Prednisolone—ankylosing spondylitis	0.000671	0.00694	CcSEcCtD
Dapagliflozin—Infestation NOS—Methylprednisolone—ankylosing spondylitis	0.000628	0.0065	CcSEcCtD
Dapagliflozin—Infestation—Methylprednisolone—ankylosing spondylitis	0.000628	0.0065	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Triamcinolone—ankylosing spondylitis	0.000621	0.00642	CcSEcCtD
Dapagliflozin—Diabetes mellitus—Methotrexate—ankylosing spondylitis	0.00062	0.00642	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Methylprednisolone—ankylosing spondylitis	0.000619	0.00641	CcSEcCtD
Dapagliflozin—Myocardial infarction—Triamcinolone—ankylosing spondylitis	0.000617	0.00639	CcSEcCtD
Dapagliflozin—Myocardial infarction—Methylprednisolone—ankylosing spondylitis	0.000616	0.00637	CcSEcCtD
Dapagliflozin—Polyuria—Methotrexate—ankylosing spondylitis	0.000615	0.00636	CcSEcCtD
Dapagliflozin—SLC5A11—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000578	0.0632	CbGpPWpGaD
Dapagliflozin—Acute coronary syndrome—Dexamethasone—ankylosing spondylitis	0.000563	0.00583	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Betamethasone—ankylosing spondylitis	0.000563	0.00583	CcSEcCtD
Dapagliflozin—Myocardial infarction—Dexamethasone—ankylosing spondylitis	0.00056	0.00579	CcSEcCtD
Dapagliflozin—Myocardial infarction—Betamethasone—ankylosing spondylitis	0.00056	0.00579	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Methylprednisolone—ankylosing spondylitis	0.000554	0.00573	CcSEcCtD
Dapagliflozin—Cerebrovascular accident—Methotrexate—ankylosing spondylitis	0.000551	0.0057	CcSEcCtD
Dapagliflozin—Malnutrition—Methylprednisolone—ankylosing spondylitis	0.000491	0.00508	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Prednisone—ankylosing spondylitis	0.000491	0.00508	CcSEcCtD
Dapagliflozin—Angioedema—Prednisolone—ankylosing spondylitis	0.000489	0.00506	CcSEcCtD
Dapagliflozin—Myocardial infarction—Prednisone—ankylosing spondylitis	0.000488	0.00505	CcSEcCtD
Dapagliflozin—Back pain—Triamcinolone—ankylosing spondylitis	0.000476	0.00493	CcSEcCtD
Dapagliflozin—Hypertension—Prednisolone—ankylosing spondylitis	0.000462	0.00478	CcSEcCtD
Dapagliflozin—Discomfort—Prednisolone—ankylosing spondylitis	0.00045	0.00466	CcSEcCtD
Dapagliflozin—Angioedema—Triamcinolone—ankylosing spondylitis	0.00045	0.00465	CcSEcCtD
Dapagliflozin—Angioedema—Methylprednisolone—ankylosing spondylitis	0.000449	0.00464	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Prednisone—ankylosing spondylitis	0.000439	0.00454	CcSEcCtD
Dapagliflozin—Oedema—Prednisolone—ankylosing spondylitis	0.000437	0.00452	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Prednisolone—ankylosing spondylitis	0.000437	0.00452	CcSEcCtD
Dapagliflozin—Dysuria—Methotrexate—ankylosing spondylitis	0.000436	0.00451	CcSEcCtD
Dapagliflozin—Hypertension—Triamcinolone—ankylosing spondylitis	0.000425	0.0044	CcSEcCtD
Dapagliflozin—Hypertension—Methylprednisolone—ankylosing spondylitis	0.000424	0.00439	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Prednisolone—ankylosing spondylitis	0.000422	0.00437	CcSEcCtD
Dapagliflozin—SLC5A4—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000422	0.0461	CbGpPWpGaD
Dapagliflozin—Infestation NOS—Methotrexate—ankylosing spondylitis	0.000416	0.0043	CcSEcCtD
Dapagliflozin—Infestation—Methotrexate—ankylosing spondylitis	0.000416	0.0043	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—ankylosing spondylitis	0.000415	0.0043	CcSEcCtD
Dapagliflozin—Discomfort—Triamcinolone—ankylosing spondylitis	0.000414	0.00428	CcSEcCtD
Dapagliflozin—Discomfort—Methylprednisolone—ankylosing spondylitis	0.000413	0.00427	CcSEcCtD
Dapagliflozin—Renal failure—Methotrexate—ankylosing spondylitis	0.000409	0.00423	CcSEcCtD
Dapagliflozin—Angioedema—Betamethasone—ankylosing spondylitis	0.000408	0.00422	CcSEcCtD
Dapagliflozin—Angioedema—Dexamethasone—ankylosing spondylitis	0.000408	0.00422	CcSEcCtD
Dapagliflozin—Oedema—Triamcinolone—ankylosing spondylitis	0.000402	0.00416	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Triamcinolone—ankylosing spondylitis	0.000402	0.00416	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Methylprednisolone—ankylosing spondylitis	0.000401	0.00415	CcSEcCtD
Dapagliflozin—Infection—Triamcinolone—ankylosing spondylitis	0.000399	0.00413	CcSEcCtD
Dapagliflozin—Infection—Methylprednisolone—ankylosing spondylitis	0.000398	0.00412	CcSEcCtD
Dapagliflozin—Skin disorder—Methylprednisolone—ankylosing spondylitis	0.000389	0.00403	CcSEcCtD
Dapagliflozin—Malnutrition—Prednisone—ankylosing spondylitis	0.000389	0.00402	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Triamcinolone—ankylosing spondylitis	0.000388	0.00402	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Methylprednisolone—ankylosing spondylitis	0.000387	0.00401	CcSEcCtD
Dapagliflozin—Hypertension—Betamethasone—ankylosing spondylitis	0.000386	0.00399	CcSEcCtD
Dapagliflozin—Hypertension—Dexamethasone—ankylosing spondylitis	0.000386	0.00399	CcSEcCtD
Dapagliflozin—Discomfort—Dexamethasone—ankylosing spondylitis	0.000376	0.00389	CcSEcCtD
Dapagliflozin—Discomfort—Betamethasone—ankylosing spondylitis	0.000376	0.00389	CcSEcCtD
Dapagliflozin—Hypotension—Methylprednisolone—ankylosing spondylitis	0.000374	0.00387	CcSEcCtD
Dapagliflozin—SLC5A4—Carbohydrate metabolism—B3GNT2—ankylosing spondylitis	0.000372	0.0407	CbGpPWpGaD
Dapagliflozin—Urinary tract disorder—Methotrexate—ankylosing spondylitis	0.000369	0.00381	CcSEcCtD
Dapagliflozin—Urethral disorder—Methotrexate—ankylosing spondylitis	0.000366	0.00379	CcSEcCtD
Dapagliflozin—Oedema—Dexamethasone—ankylosing spondylitis	0.000364	0.00377	CcSEcCtD
Dapagliflozin—Oedema—Betamethasone—ankylosing spondylitis	0.000364	0.00377	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Dexamethasone—ankylosing spondylitis	0.000364	0.00377	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Betamethasone—ankylosing spondylitis	0.000364	0.00377	CcSEcCtD
Dapagliflozin—Infection—Dexamethasone—ankylosing spondylitis	0.000362	0.00375	CcSEcCtD
Dapagliflozin—Infection—Betamethasone—ankylosing spondylitis	0.000362	0.00375	CcSEcCtD
Dapagliflozin—Angioedema—Prednisone—ankylosing spondylitis	0.000355	0.00368	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Dexamethasone—ankylosing spondylitis	0.000352	0.00364	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Betamethasone—ankylosing spondylitis	0.000352	0.00364	CcSEcCtD
Dapagliflozin—Urticaria—Prednisolone—ankylosing spondylitis	0.000347	0.00359	CcSEcCtD
Dapagliflozin—Hypotension—Dexamethasone—ankylosing spondylitis	0.000341	0.00352	CcSEcCtD
Dapagliflozin—Hypotension—Betamethasone—ankylosing spondylitis	0.000341	0.00352	CcSEcCtD
Dapagliflozin—Hypertension—Prednisone—ankylosing spondylitis	0.000336	0.00347	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—ankylosing spondylitis	0.000329	0.0034	CcSEcCtD
Dapagliflozin—Discomfort—Prednisone—ankylosing spondylitis	0.000327	0.00338	CcSEcCtD
Dapagliflozin—Malnutrition—Methotrexate—ankylosing spondylitis	0.000325	0.00336	CcSEcCtD
Dapagliflozin—Hypersensitivity—Prednisolone—ankylosing spondylitis	0.000322	0.00333	CcSEcCtD
Dapagliflozin—SLC5A1—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.00032	0.0349	CbGpPWpGaD
Dapagliflozin—SLC5A2—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.00032	0.0349	CbGpPWpGaD
Dapagliflozin—Urticaria—Triamcinolone—ankylosing spondylitis	0.000319	0.0033	CcSEcCtD
Dapagliflozin—Urticaria—Methylprednisolone—ankylosing spondylitis	0.000318	0.00329	CcSEcCtD
Dapagliflozin—Body temperature increased—Triamcinolone—ankylosing spondylitis	0.000318	0.00328	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Prednisone—ankylosing spondylitis	0.000317	0.00328	CcSEcCtD
Dapagliflozin—Oedema—Prednisone—ankylosing spondylitis	0.000317	0.00328	CcSEcCtD
Dapagliflozin—Infection—Prednisone—ankylosing spondylitis	0.000315	0.00326	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Betamethasone—ankylosing spondylitis	0.000315	0.00326	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Dexamethasone—ankylosing spondylitis	0.000315	0.00326	CcSEcCtD
Dapagliflozin—Back pain—Methotrexate—ankylosing spondylitis	0.000314	0.00325	CcSEcCtD
Dapagliflozin—Skin disorder—Prednisone—ankylosing spondylitis	0.000308	0.00319	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Prednisone—ankylosing spondylitis	0.000307	0.00317	CcSEcCtD
Dapagliflozin—Hypersensitivity—Triamcinolone—ankylosing spondylitis	0.000296	0.00306	CcSEcCtD
Dapagliflozin—Hypersensitivity—Methylprednisolone—ankylosing spondylitis	0.000295	0.00305	CcSEcCtD
Dapagliflozin—Urticaria—Dexamethasone—ankylosing spondylitis	0.00029	0.003	CcSEcCtD
Dapagliflozin—Urticaria—Betamethasone—ankylosing spondylitis	0.00029	0.003	CcSEcCtD
Dapagliflozin—Dizziness—Prednisolone—ankylosing spondylitis	0.000289	0.00299	CcSEcCtD
Dapagliflozin—Body temperature increased—Dexamethasone—ankylosing spondylitis	0.000288	0.00298	CcSEcCtD
Dapagliflozin—Body temperature increased—Betamethasone—ankylosing spondylitis	0.000288	0.00298	CcSEcCtD
Dapagliflozin—SLC5A1—Carbohydrate metabolism—B3GNT2—ankylosing spondylitis	0.000282	0.0308	CbGpPWpGaD
Dapagliflozin—SLC5A2—Carbohydrate metabolism—B3GNT2—ankylosing spondylitis	0.000282	0.0308	CbGpPWpGaD
Dapagliflozin—Rash—Prednisolone—ankylosing spondylitis	0.000275	0.00285	CcSEcCtD
Dapagliflozin—Dermatitis—Prednisolone—ankylosing spondylitis	0.000275	0.00285	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—ankylosing spondylitis	0.000275	0.00284	CcSEcCtD
Dapagliflozin—Headache—Prednisolone—ankylosing spondylitis	0.000274	0.00283	CcSEcCtD
Dapagliflozin—Discomfort—Methotrexate—ankylosing spondylitis	0.000273	0.00283	CcSEcCtD
Dapagliflozin—Constipation—Prednisone—ankylosing spondylitis	0.000271	0.00281	CcSEcCtD
Dapagliflozin—Dizziness—Triamcinolone—ankylosing spondylitis	0.000266	0.00275	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Methotrexate—ankylosing spondylitis	0.000265	0.00274	CcSEcCtD
Dapagliflozin—Dizziness—Methylprednisolone—ankylosing spondylitis	0.000265	0.00274	CcSEcCtD
Dapagliflozin—Infection—Methotrexate—ankylosing spondylitis	0.000264	0.00273	CcSEcCtD
Dapagliflozin—Nausea—Prednisolone—ankylosing spondylitis	0.000259	0.00268	CcSEcCtD
Dapagliflozin—Skin disorder—Methotrexate—ankylosing spondylitis	0.000258	0.00267	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Methotrexate—ankylosing spondylitis	0.000256	0.00265	CcSEcCtD
Dapagliflozin—Rash—Triamcinolone—ankylosing spondylitis	0.000253	0.00262	CcSEcCtD
Dapagliflozin—Dermatitis—Triamcinolone—ankylosing spondylitis	0.000253	0.00262	CcSEcCtD
Dapagliflozin—Rash—Methylprednisolone—ankylosing spondylitis	0.000253	0.00261	CcSEcCtD
Dapagliflozin—Dermatitis—Methylprednisolone—ankylosing spondylitis	0.000252	0.00261	CcSEcCtD
Dapagliflozin—Urticaria—Prednisone—ankylosing spondylitis	0.000252	0.00261	CcSEcCtD
Dapagliflozin—Headache—Triamcinolone—ankylosing spondylitis	0.000252	0.0026	CcSEcCtD
Dapagliflozin—Headache—Methylprednisolone—ankylosing spondylitis	0.000251	0.0026	CcSEcCtD
Dapagliflozin—Body temperature increased—Prednisone—ankylosing spondylitis	0.000251	0.0026	CcSEcCtD
Dapagliflozin—Hypotension—Methotrexate—ankylosing spondylitis	0.000248	0.00256	CcSEcCtD
Dapagliflozin—Dizziness—Dexamethasone—ankylosing spondylitis	0.000241	0.00249	CcSEcCtD
Dapagliflozin—Dizziness—Betamethasone—ankylosing spondylitis	0.000241	0.00249	CcSEcCtD
Dapagliflozin—Nausea—Triamcinolone—ankylosing spondylitis	0.000239	0.00247	CcSEcCtD
Dapagliflozin—Nausea—Methylprednisolone—ankylosing spondylitis	0.000238	0.00246	CcSEcCtD
Dapagliflozin—Hypersensitivity—Prednisone—ankylosing spondylitis	0.000234	0.00242	CcSEcCtD
Dapagliflozin—Rash—Dexamethasone—ankylosing spondylitis	0.00023	0.00238	CcSEcCtD
Dapagliflozin—Rash—Betamethasone—ankylosing spondylitis	0.00023	0.00238	CcSEcCtD
Dapagliflozin—Dermatitis—Betamethasone—ankylosing spondylitis	0.00023	0.00238	CcSEcCtD
Dapagliflozin—Dermatitis—Dexamethasone—ankylosing spondylitis	0.00023	0.00238	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Methotrexate—ankylosing spondylitis	0.000229	0.00237	CcSEcCtD
Dapagliflozin—Headache—Dexamethasone—ankylosing spondylitis	0.000228	0.00236	CcSEcCtD
Dapagliflozin—Headache—Betamethasone—ankylosing spondylitis	0.000228	0.00236	CcSEcCtD
Dapagliflozin—Nausea—Betamethasone—ankylosing spondylitis	0.000216	0.00224	CcSEcCtD
Dapagliflozin—Nausea—Dexamethasone—ankylosing spondylitis	0.000216	0.00224	CcSEcCtD
Dapagliflozin—Urticaria—Methotrexate—ankylosing spondylitis	0.000211	0.00218	CcSEcCtD
Dapagliflozin—Dizziness—Prednisone—ankylosing spondylitis	0.00021	0.00217	CcSEcCtD
Dapagliflozin—Body temperature increased—Methotrexate—ankylosing spondylitis	0.00021	0.00217	CcSEcCtD
Dapagliflozin—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IL12B—ankylosing spondylitis	0.000201	0.022	CbGpPWpGaD
Dapagliflozin—Rash—Prednisone—ankylosing spondylitis	0.0002	0.00207	CcSEcCtD
Dapagliflozin—Dermatitis—Prednisone—ankylosing spondylitis	0.0002	0.00207	CcSEcCtD
Dapagliflozin—Headache—Prednisone—ankylosing spondylitis	0.000199	0.00206	CcSEcCtD
Dapagliflozin—Hypersensitivity—Methotrexate—ankylosing spondylitis	0.000195	0.00202	CcSEcCtD
Dapagliflozin—Nausea—Prednisone—ankylosing spondylitis	0.000189	0.00195	CcSEcCtD
Dapagliflozin—SLC5A4—Disease—ANTXR2—ankylosing spondylitis	0.000179	0.0195	CbGpPWpGaD
Dapagliflozin—Dizziness—Methotrexate—ankylosing spondylitis	0.000175	0.00181	CcSEcCtD
Dapagliflozin—Rash—Methotrexate—ankylosing spondylitis	0.000167	0.00173	CcSEcCtD
Dapagliflozin—Dermatitis—Methotrexate—ankylosing spondylitis	0.000167	0.00173	CcSEcCtD
Dapagliflozin—Headache—Methotrexate—ankylosing spondylitis	0.000166	0.00172	CcSEcCtD
Dapagliflozin—Nausea—Methotrexate—ankylosing spondylitis	0.000158	0.00163	CcSEcCtD
Dapagliflozin—SLC5A2—Disease—ANTXR2—ankylosing spondylitis	0.000135	0.0148	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—ANTXR2—ankylosing spondylitis	0.000135	0.0148	CbGpPWpGaD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL12B—ankylosing spondylitis	0.000116	0.0127	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—B3GNT2—ankylosing spondylitis	0.000105	0.0115	CbGpPWpGaD
Dapagliflozin—SLC5A4—Metabolism—B3GNT2—ankylosing spondylitis	8.82e-05	0.00965	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—B3GNT2—ankylosing spondylitis	7.98e-05	0.00873	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—B3GNT2—ankylosing spondylitis	7.98e-05	0.00873	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—ankylosing spondylitis	7.38e-05	0.00807	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—HLA-C—ankylosing spondylitis	7.05e-05	0.00771	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—B3GNT2—ankylosing spondylitis	6.68e-05	0.00731	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—B3GNT2—ankylosing spondylitis	6.68e-05	0.00731	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—IL17A—ankylosing spondylitis	6.45e-05	0.00705	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—IL12B—ankylosing spondylitis	6e-05	0.00656	CbGpPWpGaD
Dapagliflozin—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TNF—ankylosing spondylitis	5.61e-05	0.00613	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—B3GNT2—ankylosing spondylitis	5.16e-05	0.00564	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—IL1A—ankylosing spondylitis	4.41e-05	0.00482	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—CD40LG—ankylosing spondylitis	4.38e-05	0.00479	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—IL10—ankylosing spondylitis	4.38e-05	0.00479	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—HLA-A—ankylosing spondylitis	4.26e-05	0.00466	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	4.19e-05	0.00458	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—HLA-B—ankylosing spondylitis	4.17e-05	0.00456	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—HLA-A—ankylosing spondylitis	3.86e-05	0.00423	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—HLA-A—ankylosing spondylitis	3.23e-05	0.00353	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—HLA-A—ankylosing spondylitis	3.23e-05	0.00353	CbGpPWpGaD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—ankylosing spondylitis	3.22e-05	0.00352	CbGpPWpGaD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor—TNF—ankylosing spondylitis	3.22e-05	0.00352	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—B3GNT2—ankylosing spondylitis	2.35e-05	0.00257	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—ankylosing spondylitis	2.05e-05	0.00225	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor—TNF—ankylosing spondylitis	2.05e-05	0.00225	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—B3GNT2—ankylosing spondylitis	1.91e-05	0.00209	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—TNF—ankylosing spondylitis	1.67e-05	0.00182	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—B3GNT2—ankylosing spondylitis	1.47e-05	0.00161	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—B3GNT2—ankylosing spondylitis	1.1e-05	0.0012	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—B3GNT2—ankylosing spondylitis	8.76e-06	0.000958	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—B3GNT2—ankylosing spondylitis	8.26e-06	0.000903	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	8.23e-06	0.0009	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—B3GNT2—ankylosing spondylitis	8.19e-06	0.000895	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—B3GNT2—ankylosing spondylitis	7e-06	0.000765	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—B3GNT2—ankylosing spondylitis	5.4e-06	0.00059	CbGpPWpGaD
